Exhibit 99.1

FOR IMMEDIATE RELEASE

Contact:

Chris Lewis

Vice President, Investor Relations & Corporate Affairs

(949) 481-0510

clewis@glaukos.com

Glaukos Announces Second Quarter 2025 Financial Results

Aliso Viejo, CA – July 30, 2025 – Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2025. Key highlights include:

●

Record net sales of $124.1 million in Q2 2025 increased 30% year-over-year on a reported basis and 29% year-over-year on a constant currency basis.

●

Glaucoma record net sales of $103.5 million in Q2 2025 increased 36% year-over-year.

●

U.S. Glaucoma record net sales of $72.3 million in Q2 2025 increased 45% year-over-year.

●

Gross margin of approximately 78% and non-GAAP gross margin of approximately 83% in Q2 2025.

●

Raised 2025 net sales guidance to $480 million to $486 million, compared to $475 million to $485 million previously.

“Our record second quarter results reflect a sustained growth acceleration in our business driven by successful global execution of our key strategic plans,” said Thomas Burns, Glaukos chairman and chief executive officer. “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”

Second Quarter 2025 Financial Results

Net sales in the second quarter of 2025 of $124.1 million increased 30% on a reported basis, or 29% on a constant currency basis, compared to $95.7 million in the same period in 2024.

Gross margin for the second quarter of 2025 was approximately 78%, compared to approximately 76% in the same period in 2024. Non-GAAP gross margin for the second quarter of 2025 was approximately 83%, compared to approximately 82% in the same period in 2024.

Selling, general and administrative (SG&A) expenses for the second quarter of 2025 increased 26% to $83.4 million, compared to $66.2 million in the same period in 2024. Non-GAAP SG&A expenses for the second quarter of 2025 increased 27% to $83.1 million, compared to $65.5 million in the same period in 2024.

GAAP and non-GAAP research and development (R&D) expenses for the second quarter of 2025 increased 6% to $36.5 million, compared to $34.4 million in the same period in 2024.

Loss from operations in the second quarter of 2025 was $22.7 million, compared to operating loss of $30.0 million in the second quarter of 2024. Non-GAAP loss from operations in the second quarter of 2025 was $16.6 million, compared to non-GAAP operating loss of $23.7 million in the second quarter of 2024.

Net loss in the second quarter of 2025 was $19.7 million, or ($0.34) per diluted share, compared to net loss of $50.5 million, or ($1.00) per diluted share, in the second quarter of 2024. Non-GAAP net loss in the second quarter of 2025 was $13.6 million, or ($0.24) per diluted share, compared to non-GAAP net loss of $26.3 million, or ($0.52) per diluted share, in the second quarter of 2024.

Included in non-GAAP loss from operations, non-GAAP net loss and non-GAAP EPS for the second quarter of 2024 is an acquired in-process R&D (IPR&D) charge of $2.5 million, which caused the non-GAAP loss per diluted share to have an additional loss of ($0.05) in the second quarter of 2024.

The company ended the second quarter of 2025 with approximately $278.6 million in cash and cash equivalents, short-term investments and restricted cash, and no debt.

2025 Revenue Guidance

The company expects 2025 net sales to be in the range of $480 million to $486 million based on the latest foreign currency exchange rates.

Webcast & Conference Call

The company will host a conference call and simultaneous webcast today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results and provide additional information about the company’s financial outlook. A link to the webcast is available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.) or 646-307-1963 (international) and enter Conference ID 5255602. A replay of the webcast will be archived on the company’s website following completion of the call.

Quarterly Summary Document

The company has posted a document on its Investor Relations website under the “Financials & Filings – Quarterly Results” section titled “Quarterly Summary.” This Quarterly Summary document is designed to provide the investment community with a summarized and easily accessible reference document that details the key facts associated with the quarter, the state of the company’s business objectives and strategies and any forward statements or guidance the company may make. This document is provided alongside the company’s earnings press release and is designed to be read by investors before the regularly scheduled quarterly conference call. As such, today’s conference call will be in a format primarily consisting of a questions and answers session, during which Glaukos will address any queries investors have regarding the company’s results. It is the company’s goal that this format will make its quarterly earnings process more efficient and impactful for the investment community going forward.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose^® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy

utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of federal securities laws. All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without limitation, our ability to successfully commercialize our iDose TR therapy; the impact of general macroeconomic conditions including foreign currency fluctuations and future health crises on our business; our ability to continue to generate sales of our commercialized products and develop and commercialize additional products; our dependence on a limited number of third-party suppliers, some of which are single-source, for components of our products; the occurrence of a crippling accident, natural disaster, or other disruption at our primary facility, which may materially affect our manufacturing capacity and operations; securing or maintaining adequate coverage or reimbursement by third-party payors for procedures using the iStent, the iStent inject W, iAccess, iStent infinite, iDose TR, our corneal cross-linking products or other products in development, and our compliance with the requirements of participation in federal healthcare programs such as Medicare and Medicaid; our compliance with federal, state and foreign laws and regulations for the approval and sale and marketing of our products and of our manufacturing processes; the lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes; the risk of recalls or serious safety issues with our products and the uncertainty of patient outcomes; our ability to protect our information systems against cyber threats and cybersecurity incidents, and to comply with state, federal and foreign data privacy laws and regulations; our ability to protect, and the expense and time-consuming nature of protecting our intellectual property against third parties and competitors and the impact of any claims against us for infringement or misappropriation of third party intellectual property rights and any related litigation; and our ability to service our indebtedness. These and other known risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission (SEC), including in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, which was filed with the SEC on May 1, 2025, and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, which is expected to be filed with the SEC by August 11, 2025. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-

looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

Statement Regarding Use of Non-GAAP Financial Measures

To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses certain non-GAAP historical financial measures. Management makes adjustments to the GAAP measures for items (both charges and gains) that (a) do not reflect the core operational activities of the Company, (b) are commonly adjusted within the Company's industry to enhance comparability of the Company's financial results with those of its peer group, or (c) are inconsistent in amount or frequency between periods (albeit such items are monitored and controlled with equal diligence relative to core operations) (“Non-GAAP Purposes”). The Company uses the term "Non-GAAP" to exclude certain expenses, gains and losses to achieve the Non-GAAP Purposes, including external acquisition-related costs incurred to effect a business combination; amortization of intangible assets acquired in a business combination, asset purchase transaction or other contractual relationship; impairment of goodwill and intangible assets; certain in-process R&D charges; fair value adjustments to contingent consideration liabilities and pre-acquisition contingencies arising from a business combination; integration and transition costs related to business combinations; fair market value adjustments to inventories acquired in a business combination or asset purchase transaction; restructuring charges, duplicative operating expenses, or asset write-offs (or reversals) associated with exiting or significantly downsizing a business; unusual non-recurring expenses associated with inventory write-downs; gain or loss from the sale of a business; gain or loss on the mark-to-market adjustment, impairment, or sale of long-term investments; mark-to-market adjustments on derivative instruments that hedge income or expense exposures in a future period; significant legal litigation costs and/or settlement expenses or proceeds; legal and other associated expenses that are both unusual and significant related to governmental or internal inquiries; expenses, acceleration of amortization of debt issuance costs and gain or loss on debt extinguishment associated with the exchange or redemption of convertible senior notes; significant discrete income and other tax adjustments related to transactions as well as changes in estimated acquisition-date tax effects associated with business combinations, and the impact from implementation of tax law changes and settlements; and any other adjustment that is determined to be appropriate and consistent with the Non-GAAP Purposes. See “GAAP to Non-GAAP Reconciliations” for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure.

In addition, in order to remove the impact of fluctuations in foreign currency exchange rates, the Company also presents certain net sales information on a constant currency basis, which represents the outcome that would have resulted had exchange rates in the current period been the same as the average exchange rates in effect in the comparable prior period. See “Reported Sales vs. Prior Periods” for a presentation of certain net sales information on a reported, GAAP and a constant currency basis.

GLAUKOS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except per share amounts)


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2025		2024		2025		2024
Net sales	$	124,120	$	95,690	$	230,784	$	181,312
Cost of sales		26,896		22,550		51,212		42,808
Gross profit		97,224		73,140		179,572		138,504
Operating expenses:
Selling, general and administrative		83,375		66,188		154,048		128,163
Research and development		36,538		34,426		68,891		65,152
Acquired in-process research and development		—		2,500		—		14,229
Total operating expenses		119,913		103,114		222,939		207,544
Loss from operations		(22,689)		(29,974)		(43,367)		(69,040)
Non-operating income (expense):
Interest income		2,574		2,828		5,650		5,911
Interest expense		(1,151)		(3,355)		(2,314)		(6,805)
Charges associated with convertible senior notes		—		(18,012)		—		(18,012)
Other income (expense), net		1,857		(1,701)		2,802		(2,729)
Total non-operating income (expense)		3,280		(20,240)		6,138		(21,635)
Loss before taxes		(19,409)		(50,214)		(37,229)		(90,675)
Income tax provision		248		331		574		708
Net loss	$	(19,657)	$	(50,545)	$	(37,803)	$	(91,383)

Basic and diluted net loss per share	$	(0.34)	$	(1.00)	$	(0.66)	$	(1.82)

Weighted-average shares outstanding used to compute basic and diluted net loss per share		57,205		50,715		56,922		50,169

GLAUKOS CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except par values)


	June 30,		December 31,
	2025		2024
	(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	100,813	$	169,626
Short-term investments		173,973		149,289
Accounts receivable, net		82,985		60,744
Inventory		64,621		57,678
Prepaid expenses and other current assets		13,673		12,455
Total current assets		436,065		449,792
Restricted cash		3,834		4,733
Property and equipment, net		111,816		97,867
Operating lease right-of-use asset		31,985		30,254
Finance lease right-of-use asset		40,610		41,816
Intangible assets, net		270,491		263,445
Goodwill		66,710		66,134
Deposits and other assets		25,447		20,715
Total assets	$	986,958	$	974,756

Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$	13,684	$	13,026
Accrued liabilities		65,452		62,099
Total current liabilities		79,136		75,125
Operating lease liability		36,200		33,936
Finance lease liability		68,823		69,463
Deferred tax liability, net		6,910		6,928
Other liabilities		30,777		22,373
Total liabilities		221,846		207,825

Stockholders' equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding as of June 30, 2025 and December 31, 2024		—		—
Common stock, $0.001 par value; 150,000 shares authorized; 57,277 and 56,472 shares issued and 57,249 and 56,544 shares outstanding at June 30, 2025 and December 31, 2024, respectively		57		56
Additional paid-in capital		1,545,557		1,509,831
Accumulated other comprehensive income		2,872		2,615
Accumulated deficit		(783,242)		(745,439)
Less treasury stock (28 shares as of June 30, 2025 and December 31, 2024)		(132)		(132)
Total stockholders' equity		765,112		766,931
Total liabilities and stockholders' equity	$	986,958	$	974,756

GLAUKOS CORPORATION

GAAP to Non-GAAP Reconciliations

(in thousands, except per share amounts and percentage data)

(unaudited)

	Q2 2025									Q2 2024
	GAAP			Adjustments			Non-GAAP			GAAP			Adjustments			Non-GAAP

Cost of sales	$	26,896		$	(5,764)	(a)(b)	$	21,132		$	22,550		$	(5,523)	(a)	$	17,027
Gross Margin		78.3	%		4.7	%		83.0	%		76.4	%		5.8	%		82.2	%

Operating expenses:
Selling, general and administrative	$	83,375		$	(295)	(c)	$	83,080		$	66,188		$	(705)	(d)	$	65,483
Loss from operations	$	(22,689)		$	6,059		$	(16,630)		$	(29,974)		$	6,228		$	(23,746)

Non-operating (expense) income:
Charges associated with convertible senior notes	$	—		$	—		$	—		$	(18,012)		$	18,012	(e)	$	—
Net loss	$	(19,657)		$	6,059	(f)	$	(13,598)		$	(50,544)		$	24,240	(f)	$	(26,304)
Basic and diluted net loss per share	$	(0.34)		$	0.10		$	(0.24)		$	(1.00)		$	0.48		$	(0.52)

(a)	Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $5.5 million in Q2 2025 and Q2 2024.

(b)	Mobius acquisition-related amortization expense of developed intellectual property and distribution rights of $0.2 million.

(c)	Mobius acquisition-related transaction expense.

(d)	Avedro acquisition-related amortization expense of customer relationship intangible assets.

(e)	Expenses associated with the exchange of convertible senior notes, consisting of a non-cash inducement charge of $17.4 million and direct transaction costs of $0.6 million.

(f)	Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2025 and 2024.

GLAUKOS CORPORATION

GAAP to Non-GAAP Reconciliations

(in thousands, except per share amounts and percentage data)

(unaudited)


	Year-to-Date Q2 2025									Year-to-Date Q2 2024
	GAAP			Adjustments			Non-GAAP			GAAP			Adjustments			Non-GAAP

Cost of sales	$	51,212		$	(11,287)	(a)(b)	$	39,925		$	42,808		$	(11,046)	(a)	$	31,762
Gross Margin		77.8	%		4.9	%		82.7	%		76.4	%		6.1	%		82.5	%

Operating expenses:
Selling, general and administrative	$	154,048		$	(295)	(c)	$	153,753		$	128,163		$	(1,410)	(d)	$	126,753
Loss from operations	$	(43,367)		$	11,582		$	(31,785)		$	(69,040)		$	12,456		$	(56,584)

Non-operating expense:
Charges associated with convertible senior notes	$	—		$	—		$	—		$	(18,012)		$	18,012	(e)	$	—
Net loss	$	(37,803)		$	11,582	(f)	$	(26,221)		$	(91,382)		$	30,468	(f)	$	(60,914)
Basic and diluted net loss per share	$	(0.66)		$	0.20		$	(0.46)		$	(1.82)		$	0.61		$	(1.21)

(a)	Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $11.0 million year-to-date Q2 2025 and year-to-date Q2 2024.

(b)

Mobius acquisition-related amortization expense of developed intellectual property and distribution rights of $0.2 million.

(c)

Mobius acquisition-related transaction expense.

(d)

Avedro acquisition-related amortization expense of customer relationship intangible assets of $1.4 million.

(e)

Expenses associated with the exchange of convertible senior notes, consisting of a non-cash inducement charge of $17.4 million and direct transaction costs of $0.6 million.

(f)

Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2025 and 2024.


Reported Sales vs. Prior Periods (in thousands)
							Year-over-Year Percent Change						Quarter-over-Quarter Percent Change
	2Q 2025		2Q 2024		1Q 2025		Reported		Operations (1)		Currency (2)		Reported		Operations (1)		Currency (2)
International Glaucoma	$	31,251	$	26,131	$	29,009	19.6	%	15.5	%	4.1	%	7.7	%	2.1	%	5.6	%

Total Net Sales	$	124,120	$	95,690	$	106,664	29.7	%	28.6	%	1.1	%	16.4	%	14.8	%	1.6	%

(1)

Operational growth excludes the effect of translational currency

(2)

Calculated by converting the current period numbers using the prior period’s average foreign exchange rates

GLAUKOS Corp 8-K